Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F07%3A00022440" target="_blank" >RIV/00216224:14110/07:00022440 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
Original language description
The aim of this study was to investigate if Thalidomide or Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers in patients with relapsed multiple myeloma (MM). We have focused on four chromosomal aberrations known as negative prognostic factors in MM treated by conventional or myeloablative treatment: deletion of 13q14, deletion of 17p13 (p53), translocation t(4;14) and amplification of CKS1B gene (amp1q21). We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Two groups of patients with relapsed multiple myeloma of similar age, sex, stage of the disease and other parameters were treated by Thalidomide based regimens (24 patients) and by Bortezomib based regimens (18 patients). In our preliminary experiments, we did not find statistically significant difference in OS and TTP between patients with/without chromosomal aberrations (del p
Czech name
Klinický význam delece 13q14 a 17p13, translokace t(4;14) a amplifikace 1q21 u relabujících pacientů s mnohočetným myelomem léčených novými typy léků (Thalidomid a Velcade)
Czech description
Práce se zabývá klinickým významem přítomnosti delece 13q14, delece genu p53, translokace t(4;14) a amplifikace 1q21 u relabovaných pacientů s mnohočetným myelomem léčených novými typy léků (Thalidomid a Velcade).
Classification
Type
D - Article in proceedings
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LC06027" target="_blank" >LC06027: University Research Centre - Czech Myeloma Group</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2007
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Article name in the collection
Chromosome Research
ISBN
—
ISSN
0967-3849
e-ISSN
—
Number of pages
2
Pages from-to
185-186
Publisher name
Springer
Place of publication
Netherlands
Event location
Instanbul
Event date
Jul 7, 2007
Type of event by nationality
WRD - Celosvětová akce
UT code for WoS article
—